Talampanel in Treating Patients With Recurrent High-Grade Glioma

Phase 2 Completed National Institutes of Health Clinical Center (CC) National Cancer Institute (NCI) · collab

Open-labelTreatment

Summary

RATIONALE: Drugs used in chemotherapy such as talampanel use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: This phase II trial is studying how well talampanel works in treating patients with recurrent, progressive high-grade glioma.

Timeline

Start: 2003-06
Primary completion: —
Completion: 2007-02

Outcome

Missed primary endpoint

paper The PFS6 was 4.6% for the initial 22 GBM patients, and the study was terminated early due to treatment futility; PMID 20143438 ↗

paper Talampanel was well-tolerated but had no significant activity as a single agent in unselected recurrent malignant gliomas. PMID 20143438 ↗

Publications

Results Iwamoto FM, Kreisl TN, Kim L, Duic JP, Butman JA, Albert PS, Fine HA. Phase 2 trial of talampanel, a glutamate receptor inhibitor, for adults with recurrent malignant gliomas. Cancer. 2010 Apr 1;116(7):1776-82. doi: 10.1002/cncr.24957.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Talampanel	Small molecule	—	Oral